2007: Epidemiology and Health Services Research I
Search or Browse by Day

Epidemiology and Health Services Research I

70
Change in Medical Expenditure and Job Loss after Abatacept Treatment
71
Incremental Cost-Effectiveness of Proton Pump Inhibitors for the Prevention of NSAID Ulcers: A Pharmacoeconomic Analysis Linked to a Case-Control Study
72
Under-Utilisation of Gastroprotective Drugs in Patients with NSAID-Related Ulcers
73
Access to the Rheumatologist for Early Arthritis Patients: What are the Determinants of Delayed Specialized Care? Results from the ESPOIR Cohort
74
Who Receives Biologics For Treatment Of RA?
75
Comparison between Rheumatologists’ Practice and Clinical Guidelines. How Far They Are? Results from the ESPOIR Cohort
76
Work Characteristics Associated with Sick Leave in Patients with Early Inflammatory Joint Complaints
77
Productivity Losses at Work: Comparisons of Different Measurement Instruments
78
Direct Healthcare Costs of Systemic Lupus Erythematosus and Predictors of Costs
79
The Direct Medical Expenditures and Work Productivity Costs to Employers for Patients with Systemic Lupus Erythematosus, in Comparison to Other High Cost and High Prevalence Conditions
80
Costs and Benefits of Strategies for Treating New Onset Rheumatoid Arthritis within 12 Weeks
81
Cost-Effectiveness of Abatacept in Patients with Moderately to Severely Active Rheumatoid Arthritis and Inadequate Response to Tumor Necrosis Factor α Inhibitors
82
The Impact of Anti-Tumor Necrosis Factors on Healthcare Costs in Patients with Immune Mediated Inflammatory Diseases
83
Modeling Cost-Effectiveness of Abatacept versus Infliximab in Patients with Rheumatoid Arthritis (RA) in the US
84
Cost-Effectiveness of Total Knee Replacement (TKR) in the US: Impact of Patient Risk and Hospital Volume
85
Cost Effectiveness of Traditional Chinese Acupuncture as Adjunctive Therapy in Osteoarthritis (OA) of the Knee
86
Time to Disease Modifying Anti-Rheumatic Drug Treatment in a National, Multi-Centre, Historical Inception Cohort of Randomly Selected, Early Rheumatoid Arthritis
87
Logistic Regression Modeling and Bootstrap Validation of Predictors of Early Treatment with Disease Modifying Anti-Rheumatic Drugs (DMARDs) in a National, Multi-Centre, Historical Inception Cohort of Randomly Selected, Early Rheumatoid Arthritis (RA)
88
Rheumatologic Clinical Management in a National, Multi-Centre, Historical Inception Cohort of Randomly Selected Early Rheumatoid Arthritis (RA)
89
Prevalence and Costs of Gout in Patients with Chronic Kidney Disease in a Privately Insured Population
90
The Agreement with the Dutch Regulation for Reimbursement of Anti-tnfa for Patients with Rheumatoid Arthritis in Daily Clinical Practice Discussed
91
Arthritis-Related Drug Use in a Population Based Cohort: Are There Differences by Gender and Age?
92
Why are People with Rheumatoid Arthritis (RA) not using DMARDs?-Understanding Gaps in Care
93
Nation-Wide Utilization of DMARDS in Patients with Rheumatoid Arthritis in the Veterans Health Administration (VHA)
94
Scientific Validity of Clinical Practice Guidelines for the Use Oo Infliximab and Etanercept in Rheumatoid Arthritis
95
Systematic Review of Reviews on the Use of Biologics for Rheumatoid Arthritis
96
Discontinuing, Switching, or Adding of Nonsteroidal Anti-Inflammatory Drugs among Osteoarthritis Patients
97
Underused Resources? People with Hip and Knee Pain do not Consult Health Care Professionals
98
Effect of Adalimumab Combination Therapy on Work Performance: Results from a Companion Study to PREMIER
99
Determinants of Return to Employment in Rheumatoid Arthitis (RA) in the United States from the CORRONA Registry
100
Short-Term Impact of Adalimumab on Productivity Outcomes in Patients with Rheumatoid Arthritis
101
Relationship Between Health-Related Quality of Life and Employment Outcomes During Adalimumab (ADA) Plus Methotrexate (MTX) Combination Therapy Versus MTX Monotherapy in Patients with Early Rheumatoid Arthritis
102
The Effects of Rheumatoid Arthritis on Work Performance and Retention in an Employed Population
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>